Autosomal Dominant Polycystic Kidney Disease Market to Surge at a Significant CAGR of 14.5% by 2032 | DelveInsight
Retrieved on:
Monday, September 19, 2022
Adult, Pediatrics, PKD1, Urology, Research, PKD, Patient, Physician, United Kingdom, PKD2, Kidney, Disease, Mario Negri Institute for Pharmacological Research, AL, Diet, Pharmacological Research, Kadmon Corporation, Prevalence, Back pain, Pain, Polycystic kidney disease, Time-invariant system, Risk, Population, Autosome, Tolvaptan, Otsuka Pharmaceutical, Water, Reata Pharmaceuticals, HIV disease progression rates, Regulus Therapeutics, Ryukyu Kingdom, Cyst, LAS, Genetic counseling, Nephrology, LAR, Headache, Therapy, Galapagos NV, Pharmaceutical industry, Lithium, Tesevatinib, ADPKD, Bardoxolone methyl
LAS VEGAS, Sept. 19, 2022 /PRNewswire/ -- DelveInsight's ADPKD Market Insights report includes a comprehensive understanding of current treatment practices, ADPKD emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].
Key Points:
- In addition, the approval and entry of new drugs will change the ADPKD market dynamics in the future.
- As per DelveInsight estimates, the ADPKDmarket size in the 7MM was approximately USD 1,077 million in 2021.
- Autosomal dominant polycystic kidney disease also called "adult PKD," is the most common inherited kidney disorder characterized by cyst growth in the kidneys, which increases with disease progression and results in renal failure.
- Implementing these measures early in the disease should slow the progression of kidney (renal) disease and, to some extent, preserve kidney function.